ALDX
$1.24
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical t...
Recent News
Aldeyra Therapeutics Shares Fall Pre-Bell After US FDA Response Cites Lack of Efficacy Data for Dry Eye Drug
Aldeyra Therapeutics (ALDX) shares were down more than 73% in recent Tuesday premarket activity afte
SSR Mining Stock Up 180% as New $5 Million Stake Signals Gold Conviction
SSR Mining runs a diversified portfolio of gold, silver, and base metal mines across four continents with a vertically integrated model.
Nuvation Bio Stock Up 130% This Past Year as One Fund Discloses $3 Million Buy
This clinical-stage biotech advances oncology therapies with a pipeline of novel small molecule inhibitors for hard-to-treat cancers.
Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?
Here is how Aldeyra Therapeutics, Inc. (ALDX) and Iovance Biotherapeutics (IOVA) have performed compared to their sector so far this year.
Aldeyra Therapeutics CEO Highlights Reproxalap Ahead of March 16 FDA Decision at Oppenheimer Conference
Aldeyra Therapeutics (NASDAQ:ALDX) CEO Todd Brady provided an update on the company’s late-stage ophthalmology programs and broader pipeline during a fireside chat at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference, with much of the discussion centered on the pending FDA decision for r